Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Phase 1 Completed 35 enrolled Dartmouth-Hitchcock Medical Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have advanced solid tumors.

Timeline

Start: 2000-03
Primary completion: 2005-10
Completion: 2005-10

Publications

Results Dragnev KH, Hardin SB, Pipas JM, Davis TH, Rigas JR. A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors. Chemotherapy. 2010;56(2):135-41. doi: 10.1159/000313526. Epub 2010 Apr 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	55 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	65 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	85 mg/m2	Intravenous
Background	Gemcitabine	Small molecule	3000 mg/m2	Intravenous
Background	filgrastim	Protein / enzyme biologic	—	Subcutaneous

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications